無料セミナー : 2018年10月2日『プレシジョン・メディシンの戦略的分析、将来動向予測』 BIS Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の分子診断市場:技術、応用領域、製品、エンドユーザー、地域別 - 成長、動向、予測(2018年〜2023年)

Global Molecular Diagostics Market - Segmented by Technology, Application, Product, End-Users and Geography - Growth, Trends and Forecasts (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 612996
出版日 ページ情報 英文 108 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
世界の分子診断市場:技術、応用領域、製品、エンドユーザー、地域別 - 成長、動向、予測(2018年〜2023年) Global Molecular Diagostics Market - Segmented by Technology, Application, Product, End-Users and Geography - Growth, Trends and Forecasts (2018 - 2023)
出版日: 2018年02月08日 ページ情報: 英文 108 Pages
概要

世界の分子診断市場は、2017年に70億米ドルと評価され、2018年から2023年にかけては9%のCAGRで推移すると予測されています。地域別では北米が最大となっておりそれに欧州が続いています。アジア太平洋地位は同期間において約15%のCAGRで成長する見通しです。

当レポートでは、世界の分子診断市場を調査し、市場の概要、技術・応用領域・製品・エンドユーザー・地域別の市場動向、市場規模の推移と予測、市場シェア、市場促進・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、機会と挑戦分析(DROC)

  • 市場の成長要因
    • 世界的な細菌性・ウイルス性伝染病の発生
    • POC診断の需要増加
    • 薬理ゲノミクス
    • 技術の急速な発展
  • 市場の阻害要因
    • 経済の低迷
    • 高性能検査センターの必要性
    • 限られた予算
  • 市場機会
  • 主な課題

第7章 世界の分子診断市場:市場セグメント

  • 技術別
    • In-Situハイブリダイゼーション
    • DNAチップ・DNAマイクロアレイ
    • 質量分析
    • DNAシーケンシング
    • ポリメラーゼ連鎖反応(PCR)
    • 細胞遺伝学
    • 遺伝子発現に基づく手法
    • 分子イメージング
  • 応用領域別
    • 感染症
    • 腫瘍学
    • 薬理ゲノミクス
    • 微生物学
    • 遺伝病スクリーニング
    • ヒト白血球抗原(HLA)タイピング
    • 血液スクリーニング
  • 製品別
    • 設備
    • 試薬
    • ソフトウェア・サービス
  • エンドユーザー別
    • 病院
    • 学術機関
    • 研究所
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • 合併・買収
  • 合意、提携、強力
  • 新製品の発売

第9章 主要プレーヤー

  • Roche Diagnostics
  • Illumina, Inc.
  • Hologic Corporation
  • Agilent Technologies/Dako
  • Qiagen
  • Myriad Genetics
  • Bd (Becton, Dickinson And Company)
  • Abbott Laboratories
  • Cepheid Inc.
  • Genomic Health Inc.
  • その他の企業

第10章 市場の将来展望

目次
Product Code: 7148

The global molecular diagnostics market has been estimated at around USD 7000 million in 2017. The market is expected to register a CAGR of approximately 9% during the forecast period, 2018 to 2023. North America accounted for the largest market, followed by Europe, in the molecular diagnostics market. Asia-Pacific was estimated to register approximately 15% CAGR through the forecast period, 2018-2023.

Point-of-Care Diagnostics Demand

Point-of-care testing is an emerging field in diagnostics. This generalized term encompasses tests that are portable and provide rapid results. The genetic material of an infectious agent used for detection is one of the fastest-growing point-of-care test types. Near-patient and POC tests, currently, exist for a number of pathogens, such as influenza, tuberculosis (TB), and other respiratory viruses, such as Chlamydia, gonorrhea, and group A Streptococcus (GAS). These include antigen tests (most commonly lateral-flow immunochromatographic membrane-based assays and nucleic acid tests. The POC tests are widely accepted because many tests are portable, fast, fairly simple to use, and inexpensive. Along with other factors, such as large outbreaks of bacterial and viral epidemics in the world, the rapidly evolving technology is driving the molecular diagnostics market.

Budget Limit

The end users of the market include, academic and research laboratories Fluctuation in the R&D budget can adversely affect the market growth; R&D funding fluctuates by the change in spending priorities and institutional budget. There is significant uncertainty concerning government and academic research funding worldwide, as governments in the United States and European countries, in particular, focus on reducing fiscal deficits, while confronting uncertain economic growth. Funding for life science research in some emerging countries is declining. Government funding for R&D depends on the political process, which is inherently fluid and unpredictable. Focus on programs, like defense or general efforts to minimize budget deficits can be a high priority of the government. Hence, factors, like limited budgets for R&D and economic slowdown, are restraining the growth of the market, along with other factors, such as the need for high-complexity testing centers, which are also limiting the growth of the market.

North America to Dominate the Market Growth

North America accounted for the largest market, accounting for around 44% of the global market share. The availability of robust healthcare infrastructure in North America has propelled the demand for molecular diagnostics. Along with North America, Europe is also the leading region in the global molecular diagnostics market. Asia-Pacific is fastest-growing region for molecular diagnostics and portrays huge potential for growth in the future, due to increasing government initiatives, corporate investment to standardize biopharmaceutical and healthcare industries in this region. and are projected as the fastest growing markets during the forecast period.

Key Developments in the Market

December 2017: Saudi Arabia announced the exemption of certain medications and medical equipment from the 5% VAT, which is scheduled to be implemented from January of 2018. Saudi Arabia is imposing VAT in coordination with other governments in the Gulf Cooperation Council as they seek new sources of revenue in a bid to close budget deficits caused by low oil prices.

October 2017: Abbott completed acquisition of Alere Inc. It is a global manufacturer of rapid point-of-care diagnostic tests.

July 2017: Agilent Technologies had acquired molecular and sample barcoding patent portfolios of Population Genetics Technologies.

Major Players: ROCHE DIAGNOSTICS, ILLUMINA INC., HOLOGIC CORPORATION, AGILENT TECHNOLOGIES/DAKO, QIAGEN, MYRIAD GENETICS, ABBOTT LABORATORIES, CEPHEID INC., GENOMIC HEALTH INC., GRIFOLS SA amongst others.

Reasons to Purchase this Report

Current and future molecular diagnostics market outlook in the developed and emerging markets.

Analyzing various perspectives of the market with the help of Porter's five forces analysis.

The segment that is expected to dominate the market.

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players.

3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threats of New Entrants
    • 5.2.4 Threat of Substitute Product & Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Large Outbreaks of Bacterial and Viral Epidemics in the World
    • 6.1.2 Increasing Demand for Point Of Care Diagnostics
    • 6.1.3 Pharmacogenomics
    • 6.1.4 Rapidly Evolving Technologies
  • 6.2 Market Restraints
    • 6.2.1 Economic Turndown
    • 6.2.2 Need for High Complexity Testing Centers
    • 6.2.3 Limited Budget
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 Segmentation-By Technology
    • 7.1.1 In-Situ Hybridization
      • 7.1.1.1 ISH
      • 7.1.1.2 FISH
    • 7.1.2 Chips and Microarrays
    • 7.1.3 Mass Spectroscopy
    • 7.1.4 DNA Sequencing
      • 7.1.4.1 Capillary Electrophoresis (CE)
      • 7.1.4.2 Next Generation Sequencing (NGS)
    • 7.1.5 Polymerase Chain Reaction (PCR)- Based Methods
      • 7.1.5.1 Cold-PCR
      • 7.1.5.2 Digital-PCR
      • 7.1.5.3 Directlinear Analysis
      • 7.1.5.4 Quantitative Fluorescent PCR
      • 7.1.5.5 Real-Time PCR
      • 7.1.5.6 Reverse Transcriptase PCR
    • 7.1.6 Cytogenetics
    • 7.1.7 Gene Expression- Based Studies
    • 7.1.8 Molecular Imaging
      • 7.1.8.1 Optical Imaging
      • 7.1.8.2 FDG-PET
  • 7.2 By Application
    • 7.2.1 Infectious Disease
    • 7.2.2 Oncology
    • 7.2.3 Pharmacogenomics
    • 7.2.4 Microbiology
    • 7.2.5 Genetic Disease Screening
    • 7.2.6 Human Leukocyte Antigen Typing
    • 7.2.7 Blood Screening
  • 7.3 By Product
    • 7.3.1 Instruments
    • 7.3.2 Reagents
    • 7.3.3 Software and Services
  • 7.4 By End-Users
    • 7.4.1 Hospitals
    • 7.4.2 Academics
    • 7.4.3 Research Laboratories
  • 7.5 Segmentation-By Geography
    • 7.5.1 North America
      • 7.5.1.1 US
      • 7.5.1.2 Canada
      • 7.5.1.3 Mexico
    • 7.5.2 Europe
      • 7.5.2.1 France
      • 7.5.2.2 Germany
      • 7.5.2.3 UK
      • 7.5.2.4 Italy
      • 7.5.2.5 Spain
      • 7.5.2.6 Rest of Europe (RoE)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China
      • 7.5.3.2 Japan
      • 7.5.3.3 India
      • 7.5.3.4 Australia & New Zealand
      • 7.5.3.5 South Korea
      • 7.5.3.6 Rest of Asia-Pacific
    • 7.5.4 Middle East & Africa
      • 7.5.4.1 GCC
      • 7.5.4.2 South Africa
      • 7.5.4.3 Rest of the Middle East & Africa
    • 7.5.5 South America
      • 7.5.5.1 Brazil
      • 7.5.5.2 Argentina
      • 7.5.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations & Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Roche Diagnostics
  • 9.2 Illumina, Inc.
  • 9.3 Hologic Corporation
  • 9.4 Agilent Technologies/Dako
  • 9.5 Qiagen
  • 9.6 Myriad Genetics
  • 9.7 Bd (Becton, Dickinson And Company)
  • 9.8 Abbott Laboratories
  • 9.9 Cepheid Inc.
  • 9.10 Genomic Health Inc.
  • 9.11 Others

10. Future of the Market

Back to Top